Followers | 507 |
Posts | 10138 |
Boards Moderated | 0 |
Alias Born | 04/28/2014 |
Wednesday, June 03, 2015 1:27:25 PM
bullish
## source: finance.yahoo.com
Mon, 01 Jun 2015 12:00:00 GMT ~ Matinas BioPharma's MAT9001 Meets Primary and Secondary Endpoints in First Human Trial versus Vascepa(R)
[GlobeNewswire] - -- MAT9001 demonstrates superiority versus Vascepa on bioavailability, triglyceride reduction and other lipid endpoints -- -- MAT9001 is the first orally-administered dyslipidemia product reported to significantly ...
read full: http://finance.yahoo.com/news/matinas-biopharmas-mat9001-meets-primary-120000742.html
*********************************************************
Thu, 28 May 2015 11:05:00 GMT ~ Matinas BioPharma to Present at the LD Micro Invitational on June 2, 2015
[GlobeNewswire] - BEDMINSTER, N.J. -- Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company") (OTCQB:MTNB), a clinical-stage biopharmaceutical company principally focused on the development ...
read full: http://finance.yahoo.com/news/matinas-biopharma-present-ld-micro-110500100.html
*********************************************************
Wed, 27 May 2015 17:04:18 GMT ~ MATINAS BIOPHARMA HOLDINGS, INC. Financials
read full: http://finance.yahoo.com/q/is?s=mtnb
*********************************************************
Tue, 26 May 2015 11:35:00 GMT ~ Matinas BioPharma to Present at the Fourth Annual SeeThru Equity Microcap Investor Conference on May 28, 2015
[GlobeNewswire] - BEDMINSTER, N.J. -- Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company") (OTCQB:MTNB), a clinical-stage biopharmaceutical company principally focused on the development ...
read full: http://finance.yahoo.com/news/matinas-biopharma-present-fourth-annual-113500966.html
*********************************************************
Wed, 20 May 2015 12:35:00 GMT ~ Antifungals, an Overlooked Biotech Niche With Big Potential
[Accesswire] - CORAL GABLES, FL / ACCESSWIRE / May 20, 2015 / If a global competition were held for the planet's most sadly ironic places, the hospital would place very high, if not win outright. This is not only true ...
read full: http://finance.yahoo.com/news/antifungals-overlooked-biotech-niche-big-123500355.html
*********************************************************
$MTNB charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$MTNB company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/MTNB/company-info
Ticker: $MTNB
OTC Market Place: OTCQB
CIK code: 0001582554
Company name: Matinas Biopharma Holdings, Inc.
Company website: http://www.matinasbiopharma.com
Incorporated In: DE, USA
Business Description: Matinas BioPharma is a clinical stage biopharmaceutical company, founded in 2011, focused on the development of targeted therapeutics using our innovative lipid-based drug delivery platform with an initial focus on the treatment of serious fungal and bacterial infections and the development of lipid-based prescription therapeutics for the treatment of cardiovascular and metabolic conditions. We are focused on creating highly differentiated, safe and efficacious therapies utilizing our expertise in drug formulation and development in order to address significant unmet medical needs. Recent additions to our product pipeline, including MAT2203 and MAT2501, position Matinas BioPharma to become a leader in the safe and effective delivery of anti-infective therapies utilizing its proprietary lipid-crystal nano-particle cochleate formulations. We also continue to develop our cardiovascular therapeutic candidates, with a focus on completing our ongoing PK/PD study with MAT9001, which has the goal of determining superior bioavailability and enhanced efficacy over a leading therapy for hypertriglyceridemia, as well as developing a product candidate resulting from our MAT8800 discovery program for the treatment of non-alcoholic fatty liver disease. For more information, please visit www.matinasbiopharma.comLess >>
$MTNB share structure
## source: otcmarkets.com
Market Value: $62,590,737 a/o Jun 02, 2015
Shares Outstanding: 56,900,670 a/o Apr 28, 2015
Float: 40,534,760 a/o Apr 28, 2015
Authorized Shares: 150,000,000 a/o Mar 19, 2015
Par Value: Not Available
$MTNB extra dd links
Company name: Matinas Biopharma Holdings, Inc.
Company website: http://www.matinasbiopharma.com
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/MTNB/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/MTNB/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=MTNB+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=MTNB+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=MTNB+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/MTNB/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/MTNB/news - http://finance.yahoo.com/q/h?s=MTNB+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/MTNB/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/MTNB/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/MTNB/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/MTNB/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/MTNB/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/MTNB/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/MTNB/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/MTNB/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=MTNB+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/MTNB
DTCC (dtcc.com): http://search2.dtcc.com/?q=Matinas+Biopharma+Holdings%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Matinas+Biopharma+Holdings%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Matinas+Biopharma+Holdings%2C+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.matinasbiopharma.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.matinasbiopharma.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.matinasbiopharma.com
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/MTNB/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/MTNB
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/MTNB/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/MTNB/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/MTNB/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001582554&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/MTNB/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/MTNB/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/MTNB/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/MTNB/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=MTNB&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=MTNB
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/MTNB/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=MTNB+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=MTNB+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=MTNB
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=MTNB
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=MTNB+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/MTNB/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=MTNB+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/MTNB.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=MTNB
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/MTNB/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/MTNB/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/MTNB/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/MTNB/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/MTNB
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/MTNB
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/MTNB:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=MTNB
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=MTNB
$MTNB DD Notes ~ http://www.ddnotesmaker.com/MTNB
Recent MTNB News
- Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update • GlobeNewswire Inc. • 03/27/2024 08:05:00 PM
- Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation • GlobeNewswire Inc. • 03/25/2024 12:00:00 PM
- Three Patients with Invasive Fusarium Infection in Matinas BioPharma’s Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical Response • GlobeNewswire Inc. • 03/22/2024 01:15:00 PM
- Matinas BioPharma Regains Compliance with NYSE American Continued Listing Standards • GlobeNewswire Inc. • 03/22/2024 10:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2024 01:05:14 PM
- Matinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolution • GlobeNewswire Inc. • 02/26/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/20/2024 12:35:32 PM
- Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis • GlobeNewswire Inc. • 02/20/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/09/2024 12:30:25 PM
- Matinas BioPharma to Present at Biotech Showcase 2024 • GlobeNewswire Inc. • 01/03/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/27/2023 12:40:40 PM
- Matinas BioPharma Demonstrates in vivo Biological Activity and Disease Improvement in Two Inflammatory Disease Models with Oral LNC-Delivered Small Oligonucleotides • GlobeNewswire Inc. • 12/27/2023 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/21/2023 12:40:46 PM
- Matinas BioPharma Provides Update to MAT2203 Regulatory and Development Pathway Following Feedback from FDA • GlobeNewswire Inc. • 12/21/2023 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/16/2023 02:46:31 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/16/2023 02:46:29 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/16/2023 02:46:25 AM
Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors • EDXC • Mar 27, 2024 3:01 PM
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules • AUVI • Mar 27, 2024 2:51 PM
POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks • POET • Mar 27, 2024 10:52 AM
Maybacks Global Entertainment Opens 23 More Stations in Important Major Cities • AHRO • Mar 27, 2024 9:00 AM
NxGen Brands Inc. Forecast to Deliver 140% Growth in Q1 2024 • NXGB • Mar 27, 2024 7:30 AM
Kona Gold Beverages, Inc. Strategic Advancements: Covert LLC Introduces Federally Legal D9 Gummies and Revamps Innovative eCommerce Platform, Propelling Toward $12 Million Annual Revenue Goal • KGKG • Mar 26, 2024 8:30 AM